I dont understand the industry as well as i would like, but my understanding is that Mayne is focused on the US specifically because drugs are so much more expensive their than anywhere else. It does sell/manufacture to other countries as well, but the focus of capital is the US.
If the US did fix their health system to be like normal countries i expect it would hurt a lot, i dont expect Trump to fix anything, but he could still cause damage to the industry by trying, it is a risk.
From an ethics point of view, participating in the market by introducing generics (which are cheaper) can only help, and i havent seen anything to suggest that Mayne uses extreme pricing like the owners of the Epi-Pen.
Mayne is a significant shareholder in Hedgepath which has a trialling a drug which targets some types of cancer. They are building manufacturing plant in US, and also makes a fair bit from lab services, its not a company just sitting back exploiting IP, they do real work as well.
- Forums
- ASX - By Stock
- MYX
- Quantifying downside risks
Quantifying downside risks, page-3
-
- There are more pages in this discussion • 265 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
|
|||||
Last
$4.37 |
Change
-0.010(0.23%) |
Mkt cap ! $371.7M |
Open | High | Low | Value | Volume |
$4.39 | $4.44 | $4.35 | $309.7K | 70.59K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 544 | $4.37 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.39 | 139 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 544 | 4.370 |
2 | 684 | 4.360 |
1 | 545 | 4.350 |
2 | 1139 | 4.340 |
1 | 11 | 4.330 |
Price($) | Vol. | No. |
---|---|---|
4.390 | 139 | 1 |
4.420 | 139 | 1 |
4.430 | 684 | 2 |
4.440 | 5684 | 3 |
4.450 | 684 | 2 |
Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |